Oct 13 (Reuters) - Regenerative products manufacturer Direct Biologics plans to list in the United States by merging with blank-check firm Good Works II Acquisition Corp in a deal valued at $1.03 billion, including debt. (Reporting by Mehnaz Yasmin in Bengaluru; Editing by Devika Syamnath)
Good Works II Acquisition Corp.
Equities
GWII
US38216G1040
Investment Holding Companies
1st Jan change | Capi. | |
---|---|---|
+158.06% | 6.17B | |
+0.47% | 998M | |
+2.10% | 982M | |
+41.91% | 872M | |
+22.89% | 803M | |
+1.63% | 663M | |
-1.80% | 596M | |
-.--% | 600M | |
+32.01% | 601M |